NCT04552288View on ClinicalTrials.gov

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

July 19, 2024

Study Completion Date

March 16, 2026

Conditions
Solid TumorSolid CarcinomaSolid Tumor, AdultHematologic Malignancy
Interventions
DRUG

Benralizumab

All eligible patients will receive a benralizumab dose of 30 mg SC administered by a healthcare provider once every 4 weeks for the first 3 doses, followed by once every 8 weeks for 3 additional doses.

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester, Harrison

11725

Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities), Commack

11788

Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (Limited Protocol Activities), Hauppauge

07920

Memorial Sloan Kettering Cancer Center, Basking Ridge

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER